- Home
- RARE vs MPW Comparison
RARE vs MPW Comparison
Compare RARE & MPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- MPW
- Stock Information
- Founded
- RARE 2010
- MPW 2003
- Country
- RARE United States
- MPW United States
- Employees
- RARE N/A
- MPW N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- MPW Real Estate Investment Trusts
- Sector
- RARE Health Care
- MPW Real Estate
- Exchange
- RARE Nasdaq
- MPW Nasdaq
- Market Cap
- RARE 3.3B
- MPW 3.0B
- IPO Year
- RARE 2014
- MPW 2005
- Fundamental
- Price
- RARE $37.17
- MPW $4.54
- Analyst Decision
- RARE Strong Buy
- MPW Hold
- Analyst Count
- RARE 17
- MPW 6
- Target Price
- RARE $92.29
- MPW $5.75
- AVG Volume (30 Days)
- RARE 974.0K
- MPW 8.9M
- Earning Date
- RARE 07-31-2025
- MPW 05-01-2025
- Dividend Yield
- RARE N/A
- MPW 7.05%
- EPS Growth
- RARE N/A
- MPW N/A
- EPS
- RARE N/A
- MPW N/A
- Revenue
- RARE $590,689,000.00
- MPW $994,715,000.00
- Revenue This Year
- RARE $18.94
- MPW N/A
- Revenue Next Year
- RARE $28.93
- MPW $6.93
- P/E Ratio
- RARE N/A
- MPW N/A
- Revenue Growth
- RARE 33.46
- MPW 23.40
- 52 Week Low
- RARE $29.59
- MPW $3.51
- 52 Week High
- RARE $60.37
- MPW $6.55
- Technical
- Relative Strength Index (RSI)
- RARE 55.64
- MPW 37.42
- Support Level
- RARE $35.73
- MPW $4.41
- Resistance Level
- RARE $36.22
- MPW $4.58
- Average True Range (ATR)
- RARE 1.37
- MPW 0.15
- MACD
- RARE 0.25
- MPW -0.00
- Stochastic Oscillator
- RARE 90.54
- MPW 25.00
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.